Literature DB >> 30014299

Residual vein obstruction in patients diagnosed with acute isolated distal deep vein thrombosis associated with active cancer.

F Dentali1, S Barco2, S Pegoraro3, M N D Di Minno4, D Mastroiacovo5, F Pomero6, C Lodigiani7, F Bagna3, M Sartori8, G Barillari9, N Mumoli10, M Napolitano11, S M Passamonti12, R Benedetti13, W Ageno3, M Di Nisio14.   

Abstract

After acute proximal deep vein thrombosis (DVT) the thrombotic mass decreases, especially during the first months of anticoagulation. The persistence of residual vein obstruction (RVO) may predict future recurrence in patients with cancer-associated DVT. We aimed to evaluate the proportion of patients with RVO after an episode of cancer associated isolated distal DVT (IDDVT), to identify variables associated with RVO, and to provide initial evidence of its association with recurrent VTE. We performed a post-hoc analysis of a multicenter cohort study of patients with isolated cancer-associated acute IDDVT. We included patients who underwent a control ultrasonography at the end of the anticoagulant treatment between day 30 and day 365 after index IDDVT, given that no recurrent VTE had already occurred on anticoagulant treatment. A total of 153 patients had ultrasonographic follow-up after a median of 92 days from index IDDVT: 45.8% had RVO and 54.2% exhibited complete recanalization. Female sex, Body Mass Index > 30 Kg/m2 and involvement of axial calf veins showed the strongest association with RVO. The risk of recurrence was twofold higher in patients with (versus without) RVO. RVO persisted in approximately half of patients with an episode of cancer-associated IDDVT at anticoagulant discontinuation. Patients with RVO appeared to be at a higher risk for recurrent events.

Entities:  

Keywords:  Compression ultrasound; Distal deep vein thrombosis; Recurrence; Residual vein obstruction; Venous thromboembolism

Mesh:

Substances:

Year:  2018        PMID: 30014299     DOI: 10.1007/s11239-018-1708-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  18 in total

1.  Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study.

Authors:  J-P Galanaud; M-A Sevestre; G Pernod; C Genty; S Richelet; S R Kahn; C Boulon; H Terrisse; I Quéré; J-L Bosson
Journal:  J Thromb Haemost       Date:  2017-04-21       Impact factor: 5.824

2.  Combination of D-dimer, F1+2 and residual vein obstruction as predictors of VTE recurrence in patients with first VTE episode after OAT withdrawal.

Authors:  D Poli; E Antonucci; G Ciuti; R Abbate; D Prisco
Journal:  J Thromb Haemost       Date:  2008-01-11       Impact factor: 5.824

3.  Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis.

Authors:  J-P Galanaud; M-A Sevestre; C Genty; S R Kahn; G Pernod; C Rolland; A Diard; S Dupas; C Jurus; J-M Diamand; I Quere; J-L Bosson
Journal:  J Thromb Haemost       Date:  2014-04       Impact factor: 5.824

4.  Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study.

Authors:  Mariasanta Napolitano; Giorgia Saccullo; Alessandra Malato; Delia Sprini; Walter Ageno; Davide Imberti; Doris Mascheroni; Eugenio Bucherini; Pina Gallucci; Andrea D'Alessio; Tullia Prantera; Pietro Spadaro; Stefano Rotondo; Pierpaolo Di Micco; Vincenzo Oriana; Oreste Urbano; Francesco Recchia; Angelo Ghirarduzzi; Lucio Lo Coco; Salvatrice Mancuso; Alessandra Casuccio; Giovam Battista Rini; Sergio Siragusa
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

Review 5.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

6.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

Review 7.  Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis.

Authors:  M Carrier; M A Rodger; P S Wells; M Righini; G LE Gal
Journal:  J Thromb Haemost       Date:  2011-06       Impact factor: 5.824

8.  Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism.

Authors:  S Barco; M Corti; A Trinchero; C Picchi; C Ambaglio; S V Konstantinides; F Dentali; M Barone
Journal:  J Thromb Haemost       Date:  2017-05-24       Impact factor: 5.824

Review 9.  How I treat isolated distal deep vein thrombosis (IDDVT).

Authors:  Gualtiero Palareti
Journal:  Blood       Date:  2014-01-28       Impact factor: 22.113

10.  An association between residual vein thrombosis and subclinical atherosclerosis: Cross-sectional study.

Authors:  Paolo Prandoni; Maurizio Ciammaichella; Nicola Mumoli; Nello Zanatta; Adriana Visonà; Giampiero Avruscio; Giuseppe Camporese; Eugenio Bucherini; Carlo Bova; Davide Imberti; Raffaella Benedetti; Valeria Rossetto; Franco Noventa; Marta Milan
Journal:  Thromb Res       Date:  2017-06-29       Impact factor: 3.944

View more
  2 in total

1.  Consensus statement of the Spanish Society of Internal Medicine and the Spanish Society of Medical Oncology on secondary thromboprophylaxis in patients with cancer.

Authors:  T Quintanar; C Font; E Gallardo; R Barba; B Obispo; C Díaz-Pedroche
Journal:  Clin Transl Oncol       Date:  2020-09-03       Impact factor: 3.405

2.  Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study.

Authors:  Clare White; Simon I R Noble; Max Watson; Flavia Swan; Victoria L Allgar; Eoin Napier; Annmarie Nelson; Jayne McAuley; Jennifer Doherty; Bernadette Lee; Miriam J Johnson
Journal:  Lancet Haematol       Date:  2019-02       Impact factor: 18.959

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.